Kennedy Capital Management LLC Has $28.23 Million Stake in Catalyst Pharmaceuticals, Inc. $CPRX

Posted by Francis Steltz on Jun 14th, 2026

Kennedy Capital Management LLC grew its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 14.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,209,692 shares of the biopharmaceutical company’s stock after buying an additional 149,485 shares during the period. Catalyst Pharmaceuticals accounts for about 0.6% of Kennedy Capital Management LLC’s portfolio, making the stock its 21st biggest holding. Kennedy Capital Management LLC owned approximately 0.98% of Catalyst Pharmaceuticals worth $28,234,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Cladis Investment Advisory LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $234,000. Entropy Technologies LP acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $533,000. Parkside Financial Bank & Trust lifted its position in shares of Catalyst Pharmaceuticals by 17.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 469 shares during the last quarter. Segall Bryant & Hamill LLC lifted its position in shares of Catalyst Pharmaceuticals by 78.9% in the fourth quarter. Segall Bryant & Hamill LLC now owns 143,920 shares of the biopharmaceutical company’s stock valued at $3,359,000 after buying an additional 63,452 shares during the last quarter. Finally, Walleye Capital LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $470,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CPRX has been the subject of several research reports. Stephens set a $32.00 price target on Catalyst Pharmaceuticals in a report on Thursday, May 7th. Wall Street Zen downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Robert W. Baird downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 7th. Oppenheimer downgraded Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 7th. Finally, Citigroup downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $35.00 to $31.50 in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $32.00.

Read Our Latest Stock Report on Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Price Performance

CPRX opened at $31.36 on Friday. The business has a fifty day simple moving average of $29.16 and a 200 day simple moving average of $25.63. The company has a market capitalization of $3.84 billion, a PE ratio of 18.02, a price-to-earnings-growth ratio of 0.95 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a 1 year low of $19.05 and a 1 year high of $32.56.

Catalyst Pharmaceuticals Profile

(Free Report)

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).